Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-in-human, double-blind, placebo-controlled, randomized study of ACD855 in patients with Alzheimer's disease

Next Previous
Trial Profile

First-in-human, double-blind, placebo-controlled, randomized study of ACD855 in patients with Alzheimer's disease

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 22 Aug 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACD 855 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; First in man

Most Recent Events

  • 03 May 2019 Status changed from recruiting to discontinued, according to an AlzeCure media release, as the company has decided to redirect the drug candidate ACD855 within the research platform NeuroRestore from cognitive dysfunction to an indication in the eye instead.
  • 28 Mar 2019 New trial record
  • 12 Dec 2018 According to the AlzeCure media release, results of the study are expected to be completed by mid-2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top